• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核心针活检作为三阴性乳腺癌过继细胞治疗中体外扩增 TIL 的替代来源。

Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer.

机构信息

Department of Surgery, Yale School of Medicine, Yale University, New Haven, CT.

Department of Medicine, Yale Cancer Center, Yale University, New Haven, CT.

出版信息

J Immunother. 2024;47(2):49-53. doi: 10.1097/CJI.0000000000000495. Epub 2023 Nov 22.

DOI:10.1097/CJI.0000000000000495
PMID:37991241
Abstract

Adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes (TILs) have produced long-term response in metastatic cancers. TILs have traditionally been expanded from surgically resected specimens. Ultrasound-guided core needle biopsy (CNB) is an alternative method that avoids the morbidity of surgery and have added benefits which may include patients not amenable to surgery as well as the potential to produce TILs from multiple lesions in the same patient. We assessed the ability to produce and expand TILs from primary triple-negative breast cancer tumors from CNB (n=7) and demonstrate comparable expansion, phenotype and cytokine secretion after phorbol myristate acetate-ionomycin stimulation to TILs expanded from surgery (n=6). T cell Receptor clonality and diversity were also comparable between the two cohorts throughout the TIL culture. CNB is a safe and feasible method to obtain tumor tissue for TIL generation in patients with triple-negative breast cancer.

摘要

过继输注体外扩增的肿瘤浸润淋巴细胞(TIL)已在转移性癌症中产生了长期反应。TIL 传统上是从手术切除的标本中扩增而来。超声引导下的核心针活检(CNB)是一种替代方法,可避免手术带来的发病率,并且具有一些额外的益处,包括那些不适宜手术的患者,以及有可能从同一患者的多个病变部位产生 TIL。我们评估了从 CNB 获得的原发性三阴性乳腺癌肿瘤中产生和扩增 TIL 的能力(n=7),并证明了与从手术中扩增的 TIL(n=6)相比,在佛波醇肉豆蔻酸乙酸酯-离子霉素刺激后具有相当的扩增、表型和细胞因子分泌能力。在整个 TIL 培养过程中,两组的 T 细胞受体克隆性和多样性也相似。CNB 是一种安全且可行的方法,可从三阴性乳腺癌患者中获得肿瘤组织以用于 TIL 生成。

相似文献

1
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer.核心针活检作为三阴性乳腺癌过继细胞治疗中体外扩增 TIL 的替代来源。
J Immunother. 2024;47(2):49-53. doi: 10.1097/CJI.0000000000000495. Epub 2023 Nov 22.
2
CD4/CD8 double-negative tumor-infiltrating lymphocytes expanded from solid tumor tissue suppress the proliferation of tumor cells in an MHC-independent way.从实体肿瘤组织中扩增的 CD4/CD8 双阴性肿瘤浸润淋巴细胞以 MHC 非依赖性方式抑制肿瘤细胞的增殖。
J Cancer Res Clin Oncol. 2023 Sep;149(11):9007-9016. doi: 10.1007/s00432-023-04823-x. Epub 2023 May 10.
3
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy.从肾细胞癌肿瘤中体外扩增肿瘤浸润淋巴细胞用于过继细胞治疗的生成和鉴定。
J Immunother. 2024;47(9):361-368. doi: 10.1097/CJI.0000000000000533. Epub 2024 Jul 15.
4
Role of Preoperative Breast MRI in Predicting Tumor-Infiltrating Lymphocytes in Breast Cancer: Is There an Association with Tumor Biological Subtypes?术前乳腺磁共振成像在预测乳腺癌肿瘤浸润淋巴细胞中的作用:与肿瘤生物学亚型是否存在关联?
Biomedicines. 2025 Jun 2;13(6):1364. doi: 10.3390/biomedicines13061364.
5
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
6
Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers.与转移性上皮癌肿瘤浸润淋巴细胞的生长和新抗原反应性相关的临床因素。
Cancer Immunol Immunother. 2025 Jun 19;74(8):244. doi: 10.1007/s00262-025-04091-3.
7
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.胃肠道癌中针对新抗原的肿瘤浸润淋巴细胞:一项2期试验。
Nat Med. 2025 Apr 1. doi: 10.1038/s41591-025-03627-5.
8
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.乳腺癌亚型中肿瘤浸润淋巴细胞的发生率和幅度的变化:系统评价。
JAMA Oncol. 2016 Oct 1;2(10):1354-1360. doi: 10.1001/jamaoncol.2016.1061.
9
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs).建立患者来源的结直肠肿瘤类器官与肿瘤浸润淋巴细胞(TILs)的共培养体系。
J Vis Exp. 2025 Jun 27(220). doi: 10.3791/68346.
10
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.

引用本文的文献

1
Adoptive cell therapies in thoracic malignancies: a comprehensive review.胸部恶性肿瘤的过继性细胞疗法:综述
Clin Transl Oncol. 2025 Jan 9. doi: 10.1007/s12094-024-03834-5.